LI Mei, LI Wenbo. Effect of Shengmai Powder Decoction in the treatment of patients with type 2 diabetes mellitus differentiated as syndrome of Qi and Yin deficiency combined with angina pectoris of coronary heart disease[J]. Journal of Clinical Medicine in Practice, 2020, 24(12): 77-79. DOI: 10.7619/jcmp.202012022
Citation: LI Mei, LI Wenbo. Effect of Shengmai Powder Decoction in the treatment of patients with type 2 diabetes mellitus differentiated as syndrome of Qi and Yin deficiency combined with angina pectoris of coronary heart disease[J]. Journal of Clinical Medicine in Practice, 2020, 24(12): 77-79. DOI: 10.7619/jcmp.202012022

Effect of Shengmai Powder Decoction in the treatment of patients with type 2 diabetes mellitus differentiated as syndrome of Qi and Yin deficiency combined with angina pectoris of coronary heart disease

More Information
  • Received Date: March 24, 2020
  • Objective To investigate the effect of Shengmai Powder Decoction in the treatment of patients with type 2 diabetes mellitus(T2DM)differentiated as syndrome of Qi and Yin deficiency combined with angina pectoris of coronary heart disease. Methods Totally 80 patients with T2DM differentiated as syndrome of Qi and Yin deficiency combined with angina pectoris of coronary heart disease were randomly divided into two groups, with 40 cases in each group. The control group was treated with western medicine, and the study group was treated with Shengmai Powder Decoction. The levels of serum homocysteine(Hcy)and C reactive protein(CRP), blood glucose indexes [fasting blood glucose(FPG), glycosylated hemoglobin(HbA1c), fasting insulin(FINS), and insulin resistance index(HOMA-IR)], frequency of angina pectoris, duration of each attack and electrocardiogram efficacy were compared before and after treatment between the two groups. Results After treatment, the levels of Hcy and CRP were significantly lower than those before treatment in both groups, and the study group was significantly lower than the control group(P<0.05). After treatment, the levels of FPG, HbA1c, FINS and HOMA-IR were significantly lower than those before treatment in both groups, and the study group was significantly lower than the control group(P<0.05). After treatment, the frequency of angina pectoris and duration of each attack in both groups were significantly less or shorter than those before treatment, and the study group was significantly better than the control group(P<0.05). The total effective rate in the study group was 95.00%, which was - significantly higher than 77.50% in the control group(P<0.05). Conclusion Shengmai Powder Decoction is safe and effective in the treatment of patients with T2DM differentiated as syndrome of Qi and Yin deficiency combined with angina pectoris of coronary heart disease, which can relieve the degree of inflammatory reactions, control blood glucose level, alleviate angina symptoms, and improve prognosis.
  • 吴小慧, 刘菲, 段忠心. 生脉散对2型糖尿病大鼠炎症因子及胰岛素抵抗的影响[J]. 中国动脉硬化杂志, 2018, 26(9): 895-899.
    畅辉, 岳黎明. 中西药物联用治疗气阴两虚型冠心病心绞痛75例[J]. 西部中医药, 2019, 32(8): 98-100.
    李静, 宋莉丽. 中西医结合治疗糖尿病合并冠心病心绞痛的临床观察[J]. 中华中医药学刊, 2019, 37(2): 505-508.
    中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2017年版)[J]. 中国实用内科杂志, 2018, 38(4): 292-344.
    中国心血管病预防指南(2017)写作组, 中华心血管病杂志编辑委员会. 中国心血管病预防指南(2017)[J]. 中华心血管病杂志, 2018, 46(1): 10-25.
    国家药品监督管理局. 中药新药临床研究指导原则[M]. 北京: 中国医药科技出版社, 2002: 84-85.
    唐宏霞, 董陆玲, 王新婷, 等. 益心舒胶囊治疗2型糖尿病合并冠心病心绞痛的临床疗效分析[J]. 世界中医药, 2017, 12(8): 1804-1807.
    王阶, 何庆勇. 冠心病心绞痛中医疗效评价标准[J]. 中国实验方剂学杂志, 2018, 24(15): 7-10.
    张秦风, 巩书文, 李虹, 等. 中叶素在糖尿病合并冠心病中的作用[J]. 中国动脉硬化杂志, 2018, 26(4): 424-428.
    郝清卿, 苑可心, 陈华, 等. 尼可地尔联合大剂量阿托伐他汀对冠心病合并糖尿病患者介入术后肾[J]. 中国糖尿病杂志, 2018, 26(5): 390-393.
    王森, 刘玲玲, 刘奕, 等. 尼可地尔联合前列地尔注射液治疗顽固性心绞痛的疗效分析[J]. 安徽医药, 2019, 23(4): 692-695.
    张丹丹, 刘欢, 陈嘉音, 等. 复方丹参滴丸与硝酸异山梨酯、单硝酸异山梨酯治疗冠心病心绞痛有效性和安全性的贝叶斯网状Meta分析[J]. 中国药物警戒, 2018, 15(7): 419-428.
    张德龙, 殷莉, 姜芳, 等. 丹参川芎嗪注射液联合单硝酸异山梨酯对冠心病不稳定型心绞痛血脂水平及疗效的影响[J]. 中华中医药学刊, 2019, 37(6): 1451-1454.
    马莹慧, 冯波, 朱鹤云, 等. 北五味子中总木脂素类成分的抗氧化及抗炎活性研究[J]. 食品研究与开发, 2019, 40(11): 25-30.
    吉其舰, 孙兆瑞, 杨志洲, 等. 人参皂苷Rg1对LPS诱导的肺上皮细胞凋亡和自噬的影响[J]. 中国中药杂志, 2019, 44(8): 1648-1653.
    王莹, 王华, 赵丽, 等. 麦冬多糖的提取工艺优化及其抗氧化活性分析[J]. 食品研究与开发, 2019, 40(19): 82-87.
    熊萱, 张远, 喻冬柯, 等. 中国冠心病患者ApoE基因型和高敏C反应蛋白临床相关性研究[J]. 四川医学, 2019, 40(6): 549-552.
    李镇, 邵名亮, 胡龙, 等. 血清同型半胱氨酸及载脂蛋白A-Ⅰ水平与冠心病的关联分析[J]. 安徽医药, 2019, 23(8): 1543-1546.
  • Cited by

    Periodical cited type(19)

    1. 谢有鑫,朱美飞,王晓霞,陈晓飞,夏炎通. 生脉活血汤联合达格列净治疗冠心病合并2型糖尿病疗效观察. 中华中医药学刊. 2024(02): 221-224 .
    2. 朱晓燕,徐清妍,郑玛丽,祁磊,李秀娟,郭连春,钟瑞生. 生脉散加味联合玻璃酸钠滴眼液治疗气阴两虚型2型糖尿病性干眼症的临床效果. 临床合理用药. 2024(32): 137-140 .
    3. 中华中医药学会糖尿病基层防治专家指导委员会. 国家糖尿病基层中医防治管理指南(2022). 中华糖尿病杂志. 2023(02): 100-117 .
    4. 赵璐瑶,郑浩东,陈心雨,张志君. 生脉散治疗糖尿病的临床应用进展. 糖尿病新世界. 2023(08): 189-194 .
    5. 李振,邓鑫,李萍,胡金萍,魏民敏. 冠心方联合曲美他嗪对冠心病心绞痛患者疗效、心功能的影响. 辽宁中医杂志. 2022(03): 92-95 .
    6. 庄扬名. 自拟消渴汤治疗2型糖尿病气阴两虚证的临床观察. 现代诊断与治疗. 2022(07): 969-971+982 .
    7. 徐晗. 生脉散合六味地黄汤加减治疗糖尿病的效果及安全性研究. 名医. 2022(12): 174-176 .
    8. 胡金萍,潘有龙,严世芸,邓鑫,李振,邹太波. 自拟冠心方联合西药对冠心病心绞痛病人外周淋巴细胞及microRNA-155表达的影响. 中西医结合心脑血管病杂志. 2022(18): 3370-3373 .
    9. 徐庆波,王欣,徐建华. 影响2型糖尿病并发冠心病的常见生化指标分析. 糖尿病新世界. 2022(17): 48-51 .
    10. 杨叔禹. 国家糖尿病基层中医防治管理指南(2022). 中医杂志. 2022(24): 2397-2414 .
    11. 卢明星,赵茂,王道平,曾永江,蒋文雯. 基于网络药理学-分子对接探讨黄芪生脉散对糖尿病的作用机制. 世界科学技术-中医药现代化. 2022(09): 3449-3464 .
    12. 李倩. 生脉散加减治疗气阴两虚证糖尿病合并冠心病心绞痛患者的应用效果分析. 中西医结合心血管病电子杂志. 2022(01): 61-63+77 .
    13. 朱益峰,季佳文. 芪附强心汤治疗心阳虚水泛型冠心病慢性心力衰竭的临床效果研究. 中西医结合心血管病电子杂志. 2022(02): 75-77 .
    14. 谭红梅. 不同钙离子拮抗剂治疗血管痉挛性心绞痛的疗效观察. 中国现代药物应用. 2021(05): 105-107 .
    15. 赵烨敏. 生脉散汤剂治疗2型糖尿病气阴两虚证合并冠心病心绞痛患者的效果及安全性观察. 贵州医药. 2021(03): 410-411 .
    16. 许睿婕. 生脉散合六味地黄汤加减治疗2型糖尿病对血糖、血清C肽的价值研究. 糖尿病新世界. 2021(11): 19-22 .
    17. 刘万利. 养心益气汤治疗2型糖尿病合并冠心病的疗效研究. 糖尿病新世界. 2021(12): 24-27 .
    18. 陈继玲,任珍珍,王劭敏,李园园,张亚丽. 玉泉丸合生脉散联合二甲双胍治疗气阴两虚证2型糖尿病临床研究. 陕西中医. 2021(11): 1553-1556 .
    19. 陆一玲. 探讨生脉散汤剂治疗2型糖尿病T2DM气阴两虚证合并冠心病心绞痛的疗效. 当代医学. 2021(33): 131-132 .

    Other cited types(3)

Catalog

    Article views (425) PDF downloads (15) Cited by(22)

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return